Efficacy and safety of twice-daily rabeprazole maintenance therapy for patients with reflux esophagitis refractory to standard once-daily proton pump inhibitor: the Japan-based EXTEND study

ConclusionsIn the maintenance treatment of PPI-resistant RE, rabeprazole at 10  mg b.i.d. exerted a stronger recurrence-preventing effect than 10 mg q.d. over 52 weeks. No particular safety issues were noted during long-term administration.ClinicalTrials.gov number: NCT02135107.
Source: Journal of Gastroenterology - Category: Gastroenterology Source Type: research